ERBB2 and breast carcinoma: Unresectable or metastatic HER2+ breast cancer after 2 or more anti‐HER2 regimens (2019) d; locally advanced or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma after a trastuzumab‐based regimen (2021)